Compare APPS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPS | CRVS |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | 620 | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.7M | 1.1B |
| IPO Year | 2012 | 2016 |
| Metric | APPS | CRVS |
|---|---|---|
| Price | $8.09 | $13.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.25 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 2.9M | 1.0M |
| Earning Date | 06-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,569,000.00 | N/A |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $11.34 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 38.55 | N/A |
| 52 Week Low | $2.74 | $4.05 |
| 52 Week High | $13.60 | $26.95 |
| Indicator | APPS | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 42.99 |
| Support Level | $3.85 | $12.95 |
| Resistance Level | $8.28 | $14.00 |
| Average True Range (ATR) | 0.67 | 0.71 |
| MACD | -0.20 | -0.23 |
| Stochastic Oscillator | 5.94 | 22.47 |
Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.